Moreover, prior studies in mice have reported that DMBT1-specific immune responses lead to interstitial lung disease (autoimmune syndromes), providing substantial evidence that the autoreactivity of targeting DMBT1 was pathogenic in a subset of human interstitial lung disease patients (44). This evidence concerns the gene DMBT1 and interstitial lung disease.